Career Enhancement Program
职业提升计划
基本信息
- 批准号:10708098
- 负责人:
- 金额:$ 8.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-07-01 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:AchievementAdvisory CommitteesAdvocacyApplications GrantsAwardBasic ScienceBioinformaticsBiometryBreastCategoriesClinicClinicalClinical InvestigatorClinical ResearchClinical SciencesDataDevelopmentDiagnosisDirect CostsDisabled PersonsDisciplineDiseaseEnsureEvaluationExtramural ActivitiesFacultyFundingFutureGoalsGrantIndividualLaboratoriesLeadershipMayo Clinic Cancer CenterMentorsMinorityMissionMonitorPathologyPoliciesPopulationPopulation SciencesPositioning AttributePreventionProceduresProcessProductivityQualifyingReportingResearchResearch PersonnelResearch Project GrantsResourcesScienceScientistTalentsTranslational ResearchVeteransWagesWomanWorkanticancer researchbench to bedsidecareercommunity engaged researchconvictdiversity and inclusionexpectationhealth equityimprovedmalignant breast neoplasmmortalitymultidisciplinarynext generationpatient registryprogramsrecruitskillssuccesstranslational scientistwomen with disabilities
项目摘要
PROJECT SUMMARY
The Career Enhancement Program (CEP) of the Mayo Clinic Breast Cancer SPORE is committed to identifying
and mentoring junior faculty with the greatest potential of developing independent programs in translational
breast cancer research. This is accomplished through a rigorous review process aimed at identifying the most
talented and promising candidates followed by an intensive, rigorous and effective mentoring program. The
mentoring program is based on the establishment and optimal functioning of a Multidisciplinary Mentoring
Committee led by a senior investigator with the scientific expertise and commitment to developing the next
generation of translational breast cancer researchers. The Multidisciplinary Mentoring Committee will be
composed of the primary mentor and the complementary clinical and/or basic investigator necessary for a
comprehensive mentoring program plus a statistician. It is viewed as crucial to the success of the awardee that
the mentoring be ongoing and robust. This will be accomplished by close oversight by the Director of the CEP
of the mentoring process and progress of the awardee. Dr. Goetz, the Director of the CEP and SPORE Director,
will report to the SPORE Executive Committee. This intensive oversight process was established because of the
firm conviction of the SPORE Director that the development of independent investigators and translational breast
cancer research is central to the SPORE mission. The explicit expectation is that the awardees will utilize the
resources made available to them for the development of independent research programs and acquisition of
independent funding in breast cancer research. We are requesting $50,000 per year (direct costs) to support
this program. This will be supplemented by $50,000 (direct costs) of Mayo Clinic Cancer Center support. One
award of $100,000 per year will be made, which can be used for salary, technician support, and supplies. One
awardee will be supported per year and a given awardee can be supported for up to two years providing
satisfactory progress is demonstrated. To date the CEP has been successful in that of the 10 awardees, five
have successfully competed to become either SPORE Project Co-Leaders in full Projects or Co-Directors of
Cores. Additionally, half have been women (three) or minority (two). Further, of the 3 women, 2 have been
promoted into leadership positions in the SPORE including Core B Co-Director and Core C Co-Director.
项目摘要
梅奥诊所乳腺癌孢子的职业增强计划(CEP)致力于确定
并指导初级教师具有开发转化独立计划的最大潜力
乳腺癌研究。这是通过旨在确定最多的严格审核过程来完成的
才华横溢且有前途的候选人,然后是一项密集,严格和有效的指导计划。这
指导计划基于多学科指导的建立和最佳功能
由一名高级调查员领导的科学专业知识和致力于发展下一个的委员会
转化乳腺癌研究人员的产生。多学科指导委员会将是
由主要导师和补充临床和/或基本研究者组成
全面的指导计划以及统计学家。这对获奖者的成功至关重要
指导持续不断。这将通过CEP主任的仔细监督来完成
指导过程和获奖者的进步。 CEP兼孢子主管董事Goetz博士,
将向孢子执行委员会报告。由于
对孢子主管的坚定信念,即独立研究人员和翻译乳房的发展
癌症研究是孢子任务的核心。明确的期望是获奖者将利用
他们提供的资源可用于制定独立研究计划和获取
乳腺癌研究中的独立资金。我们要求每年50,000美元(直接费用)以支持
这个程序。这将以梅奥诊所癌症中心支持的50,000美元(直接费用)补充。一
每年将颁发100,000美元的奖励,可用于工资,技术人员支持和用品。一
获奖者每年将得到支持,并且可以为特定的获奖者提供多达两年的支持
表现出令人满意的进度。迄今为止,CEP在10位获奖者中取得了成功,五个
已成功竞争成为完整项目的孢子项目共同领导者或
内核。此外,一半是女性(三个)或少数族裔(两个)。此外,在这3名妇女中,有2名是
晋升为孢子中的领导地位,包括核心B联合导演和C核C联合导演。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MATTHEW Philip GOETZ其他文献
MATTHEW Philip GOETZ的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MATTHEW Philip GOETZ', 18)}}的其他基金
Tamoxifen biotransformation pathway pharmacogenomics
他莫昔芬生物转化途径药物基因组学
- 批准号:
8523013 - 财政年份:2008
- 资助金额:
$ 8.32万 - 项目类别:
Tamoxifen biotransformation pathway pharmacogenomics
他莫昔芬生物转化途径药物基因组学
- 批准号:
7656628 - 财政年份:2008
- 资助金额:
$ 8.32万 - 项目类别:
Tamoxifen biotransformation pathway pharmacogenomics
他莫昔芬生物转化途径药物基因组学
- 批准号:
8100264 - 财政年份:2008
- 资助金额:
$ 8.32万 - 项目类别:
Tamoxifen biotransformation pathway pharmacogenomics
他莫昔芬生物转化途径药物基因组学
- 批准号:
8270377 - 财政年份:2008
- 资助金额:
$ 8.32万 - 项目类别:
Tamoxifen biotransformation pathway pharmacogenomics
他莫昔芬生物转化途径药物基因组学
- 批准号:
7848214 - 财政年份:2008
- 资助金额:
$ 8.32万 - 项目类别:
Endoxifen as a Novel Hormonal Therapy for Breast Cancer
Endoxifen 作为乳腺癌的新型激素疗法
- 批准号:
8555337 - 财政年份:2005
- 资助金额:
$ 8.32万 - 项目类别:
相似海外基金
Computer-facilitated Screening and Brief Intervention in pediatric primary care to reduce underage drinking: a large multi-site randomized trial
儿科初级保健中计算机辅助筛查和简短干预以减少未成年人饮酒:一项大型多中心随机试验
- 批准号:
10553448 - 财政年份:2020
- 资助金额:
$ 8.32万 - 项目类别: